External validation of the international IgA nephropathy prediction tool in a modern Chinese cohort

doi:10.3969/j.issn.1006-7795.2022.05.008

Abstract

Abstract: Objective To externally validate the international IgA nephropathy prediction tool in a modern Chinese cohort, so as to provide more evidence for clinical application. Methods This study included IgA nephropathy patients diagnosed by kidney puncture in Tongji Hospital Affiliated to Huazhong University of Science and Technology from January 2012 to December 2016. The predicted risk of each patient was calculated according to the international IgA nephropathy prediction tool, with the 50% decline of estimated glomerular filtration rate (eGFR) or end-stage renal failure as the endpoint. This study evaluated the performance of two models (Model 1: without racial factor; Model 2: with racial factor) in the international IgA nephropathy prediction tools in discrimination, calibration, reclassification and clinical utility. Results The median follow-up time in the modern Chinese cohort in this study was 4 years, and 48(10%) subjects reached the endpoint. The C indices of the two models were 0.86, and the survival curves were well separated, showing excellent discrimination ability. The performance of the two models in calibration is basically the same, both slightly underestimate the risk of 5 years. The reclassification indicates that there is no significant difference between the two models in predicting 5-year risks. The decision curves analysis showed that the two models were clinically practical in predicting five-year risks, and there was no significant difference between two models. Conclusion The international IgA nephropathy prediction tools showed significant discrimination, acceptable calibration and satisfactory clinical utility, and there is no significant difference between the two models.

Key words: IgA nephropathy, prognostic model, external validation

CLC Number:

R692

Guo Kanglin, Cheng Yichun, Ge Shuwang, Xu Gang. External validation of the international IgA nephropathy prediction tool in a modern Chinese cohort[J]. Journal of Capital Medical University, 2022, 43(5): 713-719.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.05.008

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I5/713

References

[1] Schena F P, Nistor I. Epidemiology of IgA nephropathy: a global perspective[J]. Semin Nephrol, 2018, 38(5): 435－442.
[2] Kim J K, Kim J H, Lee S C, et al. Clinical features and outcomes of IgA nephropathy with nephrotic syndrome[J]. Clin J Am Soc Nephrol, 2012, 7(3): 427－436.
[3] Rovin B H, Adler S G, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases[J]. Kidney Int, 2021 ,100(4):753-779.
[4] Barbour S J, Coppo R, Zhang H, et al. Evaluating a new international risk-prediction tool in IgA nephropathy[J]. JAMA Intern Med, 2019, 179(7): 942－952.
[5] Vickers A J, Elkin E B. Decision curve analysis: a novel method for evaluating prediction models[J]. Med Decis Making, 2006, 26(6): 565－574.
[6] Chen T Y, Li X, Li Y X, et al. Prediction and risk stratification of kidney outcomes in IgA nephropathy[J]. Am J Kidney Dis, 2019, 74(3): 300－309.
[7] Miyabe Y, Karasawa K, Akiyama K, et al. Grading system utilising the total score of Oxford classification for predicting renal prognosis in IgA nephropathy[J]. Sci Rep, 2021, 11(1): 3584.
[8] Coppo R, D'Arrigo G, Tripepi G, et al. Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford classification for IgA nephropathy (VALIGA) update[J]. Nephrol Dial Transplant, 2020, 35(6): 1002－1009.
[9] Beck L, Bomback A S, Choi M J, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis[J]. Am J Kidney Dis, 2013, 62(3): 403－441.
[10] Papasotiriou M, Stangou M, Chlorogiannis D, et al. Validation of the international IgA nephropathy prediction tool in the Greek registry of IgA nephropathy[J]. Front Med (Lausanne), 2022, 9: 778464.
[11] Xie J Y, Lv J C, Wang W M, et al. Kidney failure risk prediction equations in IgA nephropathy: a multicenter risk assessment study in Chinese patients[J]. Am J Kidney Dis, 2018, 72(3): 371－380.
[12] Schena F P, Anelli V W, Trotta J, et al. Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy[J]. Kidney Int, 2021, 99(5): 1179－1188.
[13] Barbour S J, Espino-Hernandez G, Reich H N, et al. The MEST score provides earlier risk prediction in lgAnephropathy[J]. Kidney Int, 2016, 89(1): 167－175.
[14] Zhao Y F, Zhu L, Liu L J, et al. Measures of urinary protein and albumin in the prediction of progression of IgA nephropathy[J]. Clin J Am Soc Nephrol, 2016, 11(6): 947－955.
[15] Hogg R. An evaluation of the roles of hematuria and uric acid in defining the prognosis of patients with IgA nephropathy[J]. Pediatr Nephrol, 2022, 37(5): 947－958.
[16] Jiang Z, Tan J X, Wang S Q, et al. Lower serum bilirubin is associated with poor renal outcome in IgA nephropathy patients[J]. Int J Med Sci, 2021, 18(13): 2964－2970.
[17] Xu D M, Lv J C, Wang J W, et al. Association between plasma phosphorus and renal outcome: a prospective cohort of patients majorly with glomerulonephritis[J]. Nephrology (Carlton), 2017, 22(1): 43－48.
[18] Haas M, Verhave J C, Liu Z H, et al. A multicenter study of the predictive value of crescents in IgA nephropathy[J]. J Am Soc Nephrol, 2017, 28(2): 691－701.
[19] Kawasaki Y, Maeda R, Ohara S, et al. Serum IgA/C3 and glomerular C3 staining predict severity of IgA nephropathy[J]. Pediatr Int, 2018, 60(2): 162－167.
[20] Heybeli C, Oktan M A, Yildiz S, et al. Clinical significance of mesangial IgM deposition in patients with IgA nephropathy[J]. Clin Exp Nephrol, 2019, 23(3): 371－379.
[21] Niel O, Bastard P. Artificial intelligence in nephrology: core concepts, clinical applications, and perspectives[J]. Am J Kidney Dis, 2019, 74(6): 803－810.
[22] Zhong Z X, Tang Y, Tan J X, et al. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria[J]. Int Urol Nephrol, 2021, 53(1): 121－127.